of Neurology afﬁrms the value of this guideline. Stroke 2006;37:
577-617.
117. Collaborative meta-analysis of randomised trials of antiplatelet
therapy for prevention of death, myocardial infarction, and stroke in
high risk patients. BMJ 2002;324:71-86.
118. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American
College of Chest Physicians Evidence-Based Clinical Practice
Guidelines (8th Edition). Chest 2008;133(6 Suppl):630s-69s.
119. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, KellyHayes M, et al. Preventing ischemic stroke in patients with prior
stroke and transient ischemic attack : a statement for healthcare
professionals from the Stroke Council of the American Heart Association. Stroke 1999;30:1991-4.
120. Johnston SC, Nguyen-Huynh MN, Schwarz ME, Fuller K, Williams CE,
Josephson SA, et al. National Stroke Association guidelines for the
management of transient ischemic attacks. Ann Neurol 2006;60:
301-13.
121. van Gijn J, Algra A, Kappelle J, Koudstaal PJ, van Latum A.
A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in
patients after a transient ischemic attack or minor ischemic stroke.
N Engl J Med 1991;325:1261-6.
122. Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J.
Antiplatelet therapy for secondary prevention of vascular disease
complications. Curr Atheroscler Rep 2017;19:56.

123. Johnson ES, Lanes SF, Wentworth CE 3rd, Satterﬁeld MH, Abebe BL,
Dicker LW. A metaregression analysis of